Skip to main content
Astellas Pharma Inc. logo

Astellas Pharma Inc. — Investor Relations & Filings

Ticker · 4503 ISIN · JP3942400007 LEI · 529900IB708DY2HBBB35 T Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2025-06-16 Annual Report
Country JP Japan
Listing T 4503

About Astellas Pharma Inc.

https://www.astellas.com/en

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. The company's core activities encompass the research, development, manufacture, and commercialization of novel pharmaceutical products. Astellas focuses on pioneering transformative therapies in disease areas with high unmet medical needs, including oncology, ophthalmology, urology, immunology, and women's health. Through its patient-centric approach and robust research and development programs, the company aims to deliver innovative healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
有価証券報告書－第20期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the header information for the fiscal year ending March 31, 2025, and includes XBRL-like tagging for financial data, confirming it is the full annual report rather than an announcement or summary. FY 2025
2025-06-16 Japanese
訂正発行登録書
Capital/Financing Update Classification · 98% confidence The document is titled "訂正発行登録書" (Corrected Shelf Registration Statement) and is submitted to the Kanto Local Finance Bureau ("関東財務局長"). It details the type of security being registered as "社債" (Corporate Bonds) and specifies the maximum issuance amount ("発行予定額"). The submission date is February 4, 2025, and it references a previous shelf registration from July 19, 2024. This document relates to financing activities and capital structure changes (issuance of bonds). Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate fit for a shelf registration statement concerning bond issuance, as it directly relates to fundraising and capital structure changes.
2025-02-04 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the '関東財務局長' (Kanto Local Finance Bureau Director) on February 4, 2025. It explicitly states that it is filed based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 12 of the Cabinet Office Ordinance on Disclosure of Corporate Information. The content details a significant event: recording an impairment loss on subsidiary shares (Ganymed Pharmaceuticals GmbH) amounting to 60.6 billion yen, which will be recorded as a special loss in the non-consolidated financial results for the fiscal year ending March 2025. This structure—a formal filing detailing a material, non-periodic event impacting financial status—is characteristic of a Japanese Extraordinary Disclosure filing, which corresponds best to the general 'Regulatory Filings' category (RNS) or potentially a specific disclosure related to financial events, but given the mandatory regulatory nature and the lack of a specific code for 'Extraordinary Report' (which is often filed as a 'Tanshin' or 'Yukashoken Hokokususho' amendment, but here is a specific form), RNS is the most appropriate general regulatory fallback for non-standard, material disclosures not covered by 10-K, ER, or IR. Since the document is a formal regulatory submission detailing a material event, RNS is selected as the best fit among the provided options for a general regulatory filing.
2025-02-04 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled with Japanese headers indicating it is a '臨時報告書' (Extraordinary Report or Timely Disclosure Report) submitted to the '関東財務局長' (Director of the Kanto Local Finance Bureau) on February 4, 2025. Section 1 explicitly states the reason for filing under Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related regulations, which mandates filing for events significantly impacting financial condition, operating results, or cash flows. Section 2 details the event: recording significant impairment losses (166.9 billion JPY) related to drug assets (IZERVAYTM and AT466) due to strategic reviews. This structure and content strongly align with a mandatory, event-driven disclosure in Japan, which typically falls under the category of a general Regulatory Filing (RNS) or, more specifically, a report detailing a major financial event that doesn't fit the standard periodic reports (10-K, IR, ER). Given the options, 'RNS' (Regulatory Filings) is the most appropriate general category for a Japanese '臨時報告書' detailing a significant, non-scheduled financial event, as it is a mandatory regulatory disclosure not covered by the specific financial report codes (10-K, IR, ER, etc.).
2025-02-04 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It contains certifications from the CEO and CFO regarding the accuracy of the semi-annual report. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 2024
2024-11-06 Japanese
半期報告書－第20期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) for Astellas Pharma Inc., covering the period from April 1, 2024, to September 30, 2024. It contains detailed financial statements, management analysis (MDA), and operational highlights, which are characteristic of an interim financial report. According to the filing definitions, this falls under the 'Interim / Quarterly Report' (IR) category. H1 2025
2024-11-06 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.